Based on these observations, the combinations between IGF-signaling inhibitors and other anti-tumor drugs, such as DNA damaging agents or kinase inhibitors, may represent a promising therapeutic strategy for undifferentiated thyroid carcinomas. The gene discussed is IGF1; the disease is thyroid gland undifferentiated (anaplastic) carcinoma.